Director Purchase

RNS Number : 0620D
Oxford Biomedica PLC
23 October 2020
 

 

 

 

Director Purchase

 

Oxford, UK - 23 October 2020:   Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Vulpes Life Sciences Fund ("Vulpes"), whose portfolio manager Martin Diggle is a Non-Executive Director on the Board of Oxford Biomedica, has purchased 25,000 ordinary shares of 50p each ("Ordinary Shares") in the Company on 22 October 2020 on the London Stock Exchange at a price of 779.6p per share. Following this purchase Vulpes Testudo/Vulpes Life Sciences Fund holds 10,738,616 ordinary shares representing 13.1% of the Company.

 

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the transaction in number of Ordinary Shares.

 

 1.

Details of the person discharging material responsibilities/person closely   associated

 

 a.

Name

Vulpes Life Sciences Fund

 2.

Reason for the notification

 

 a.

Position/status

 Martin Diggle, Non-Executive Director

 

 b.

Initial notification /amendment

 Initial notification

 

3.

Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor

 

 a.

Name

 Oxford Biomedica plc

 

 b.

Legal Entity Identifier

 213800S1GVQNXQ15K851

 

4.

Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 a.

Description of the financial instrument, type of instrument identification code

 Oxford Biomedica plc Ordinary Shares of 50p each

 

 

 GB00BDFBVT43

 

b.

Nature of the transaction

Purchase of ordinary shares

 

 

c.

Currency

 GBP - British Pound

 

d.

Price(s) and volume(s)

 

Price(s)

 

 

Volume(s)

£7.80

 

25,000

 

 

 

 

e.

Aggregated information

· Aggregated volume

· Price

· Aggregated total

 

 

25,000

 

£7.795807

£194,895.18

 

f.

Date of the transaction

 2020-10-22

 

g.

Place of the transaction

 London Stock exchange, Main List (XLON)

 

 

 

The issued share capital of the Group is 82,223,225 ordinary 50p shares.

 

 

-Ends-

 

For further information, please contact:

 

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at www.oxb.com

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZZMZGLFKGGZG
UK 100

Latest directors dealings